Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Capital Leases: 2017-2025

  • Dr Reddys Laboratories' Capital Leases rose 185570676.26% to $4.1 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $4.1 billion, marking a year-over-year increase of 185570676.26%. This contributed to the annual value of $4.1 billion for FY2025, which is 185570676.26% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Capital Leases stood at $4.1 billion for Q1 2025, which was up 185,570,676.26% from $2,190 recorded in Q1 2024.
  • In the past 5 years, Dr Reddys Laboratories' Capital Leases ranged from a high of $4.1 billion in Q1 2025 and a low of $1,278 during Q1 2023.
  • Over the past 3 years, Dr Reddys Laboratories' median Capital Leases value was $2,190 (recorded in 2024), while the average stood at $1.4 billion.
  • Data for Dr Reddys Laboratories' Capital Leases shows a peak YoY spiked of 185,570,676.26% (in 2025) over the last 5 years.
  • Over the past 4 years, Dr Reddys Laboratories' Capital Leases (Quarterly) stood at $2,499 in 2021, then reached $1,278 in 2023, then skyrocketed by 71.36% to $2,190 in 2024, then skyrocketed by 185,570,676.26% to $4.1 billion in 2025.
  • Its Capital Leases was $4.1 billion in Q1 2025, compared to $2,190 in Q1 2024 and $1,278 in Q1 2023.